RNS Announcements

2024

05 November

Director/PDMR Shareholding

01 November

Result of Requisitioned General Meeting

15 October

Publication of Circular and Notice of Requisitioned General Meeting

10 October

New Commercial Partnership in Mexico

08 October

Q3 2024 Trading Update

07 October

Appointment of Non-Executive Director

03 October

New Commercial Partnership in Ukraine

30 September

Total Voting Rights

27 September

Holding(s) in Company

25 September

Response to General Meeting Requisition

25 September

General Meeting Requisition Notice

16 September

New Commercial Partnership in Greece

06 September

Response to OptiBiotix Health plc announcement

04 September

Share Subscription and Proposed Board Appointment

30 August

Unaudited Interim Results to 30 June 2024

15 August

New commercial partnership agreement in China

08 August

Result of AGM

29 July

New appointment

15 July

Six month trading update

28 June

Final Results

2023

27 September

Unaudited Results to 30 June 2023

01 August

Distribution agreement

26 July

Result of AGM

24 July

New appointment

28 June

Final Results

04 January

Commercial and scientific update

2022

28 September

Unaudited Results to 30 June 2022

14 September

New commercialisation partner in Asia Pacific

14 June

Appointment of Chief Executive Officer

31 May

Launch of cholesterol reducing yoghurt

19 April

Change of registered office

01 April

Holding(s) in Company

31 March

Admission to trading on AQSE and first day of dealings

Latest RNS News

05 November 2024

Director/PDMR Shareholding

01 November 2024

Result of Requisitioned General Meeting

15 October 2024

Publication of Circular and Notice of Requisitioned General Meeting

Latest Interview

Aquis-listed ProBiotix Health taps into demand for cardiovascular disease treatments
Stephen O'Hara | 23 February 2023
IG UK | Youtube

Sign up for Investor Alerts

Investor Alert